MX2012007806A - Composiciones farmaceuticas para administracion oral de peptidos de insulina. - Google Patents

Composiciones farmaceuticas para administracion oral de peptidos de insulina.

Info

Publication number
MX2012007806A
MX2012007806A MX2012007806A MX2012007806A MX2012007806A MX 2012007806 A MX2012007806 A MX 2012007806A MX 2012007806 A MX2012007806 A MX 2012007806A MX 2012007806 A MX2012007806 A MX 2012007806A MX 2012007806 A MX2012007806 A MX 2012007806A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
oral administration
insulin peptides
insulin
peptides
Prior art date
Application number
MX2012007806A
Other languages
English (en)
Inventor
Florian Anders Foeger
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2012007806A publication Critical patent/MX2012007806A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con composiciones farmacéuticas apropiadas para administración oral de péptidos de insulina, métodos de hacerlas y tratamiento con las mismas.
MX2012007806A 2010-01-12 2011-01-12 Composiciones farmaceuticas para administracion oral de peptidos de insulina. MX2012007806A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10150496 2010-01-12
US29462110P 2010-01-13 2010-01-13
PCT/EP2011/050338 WO2011086093A2 (en) 2010-01-12 2011-01-12 Pharmaceutical compositions for oral administration of insulin peptides

Publications (1)

Publication Number Publication Date
MX2012007806A true MX2012007806A (es) 2012-08-01

Family

ID=42174567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007806A MX2012007806A (es) 2010-01-12 2011-01-12 Composiciones farmaceuticas para administracion oral de peptidos de insulina.

Country Status (11)

Country Link
US (2) US20130058999A1 (es)
EP (1) EP2523655A2 (es)
JP (1) JP5908847B2 (es)
KR (1) KR20120117013A (es)
CN (1) CN102753150A (es)
AU (1) AU2011206629B2 (es)
BR (1) BR112012016853A2 (es)
CA (1) CA2786953A1 (es)
MX (1) MX2012007806A (es)
RU (1) RU2012133075A (es)
WO (1) WO2011086093A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2627670A2 (en) 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
JP2015502971A (ja) 2011-12-21 2015-01-29 ノヴォ ノルディスク アー／エス Ｎ末端修飾インスリン誘導体
EP2813512B1 (en) 2011-12-28 2021-03-31 Chugai Seiyaku Kabushiki Kaisha Peptide-compound cyclization method
WO2013128003A1 (en) 2012-03-01 2013-09-06 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
JP2016525524A (ja) * 2013-07-24 2016-08-25 ノヴォ ノルディスク アー／エス 錠剤コアとアニオン性コポリマーコーティングとを含む経口インスリン投与のための医薬組成物
MX2017005883A (es) * 2014-11-04 2017-11-28 Innopharmax Inc Administracion oral de farmacos inestables o deficientemente absorbidos.
ES2880618T3 (es) * 2015-03-02 2021-11-25 Medlab Clinical U S Inc Sistemas de suministro transmucosa y transdérmico
US12168070B2 (en) 2015-03-02 2024-12-17 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3821905B1 (en) 2016-12-16 2022-10-12 Novo Nordisk A/S Insulin containing pharmaceutical compositions
WO2018124162A1 (ja) * 2016-12-28 2018-07-05 中外製薬株式会社 化合物の膜透過性を改善するための自己乳化型製剤
EP3765074A4 (en) * 2018-03-13 2021-12-29 The Regents of The University of California Virus-like nanocapsid for oral delivery of insulin
CN108743523B (zh) * 2018-06-11 2021-01-12 滕川 一种黄芪多糖制剂及其制备方法和应用
US11690963B2 (en) 2018-08-22 2023-07-04 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
US11517685B2 (en) 2019-01-18 2022-12-06 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
US20200060338A1 (en) 2018-08-22 2020-02-27 Respira Technologies, Inc. Electronic device for producing an aerosol for inhalation by a person
WO2020130649A1 (ko) * 2018-12-19 2020-06-25 대화제약 주식회사 Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물
WO2020205409A1 (en) * 2019-04-03 2020-10-08 President And Fellows Of Harvard College Ionic liquids for drug delivery
EP4044843A4 (en) * 2019-10-20 2023-12-06 Qnovia, Inc. LIQUIDS FOR AEROSOLIZATION AND INHALATION USING ELECTRONIC DEVICES
US12471625B2 (en) 2020-11-01 2025-11-18 Qnovia, Inc. Electronic devices and liquids for aerosolizing and inhaling therewith
JP7103403B2 (ja) * 2020-12-25 2022-07-20 横浜ゴム株式会社 加硫ゴム用接着前処理剤
AU2021414772A1 (en) * 2020-12-31 2023-07-20 The Governing Council Of The University Of Toronto Fully-dilutable, self-microemulsifying delivery systems (smedds) for poorly water-soluble polar solutes
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
TW202404490A (zh) 2022-04-22 2024-02-01 美商奎諾維亞公司 用於霧化和吸入液體的電子設備
KR102765361B1 (ko) * 2022-08-22 2025-02-11 부산대학교 산학협력단 폴리소르베이트-숙신산-카르니틴 복합체 및 이를 포함하는 생리활성 물질 또는 약물 전달용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229779T2 (de) 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AU1574900A (en) * 1998-12-04 2000-06-26 Provalis (Uk) Limited Pharmaceutical compositions containing insulin
CN1174741C (zh) 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
AU2002362040A1 (en) 2001-12-03 2003-06-17 Dor Biopharma Inc. Reverse micelle compositions and uses thereof
CA2531988C (en) * 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
EP1684793B1 (en) * 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
ES2391776T3 (es) * 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
US20060182771A1 (en) 2005-02-09 2006-08-17 Dor Philippe J Formulations for ocular treatment
CA2630578C (en) * 2005-11-30 2014-04-15 Generex Pharmaceuticals Inc. Orally absorbed pharmaceutical formulation and method of administration
JP5550338B2 (ja) * 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
AU2008257505B2 (en) * 2007-06-01 2013-05-16 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
AU2008288413B2 (en) * 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
WO2010060667A1 (en) * 2008-11-28 2010-06-03 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
US20120196800A1 (en) * 2009-09-16 2012-08-02 Novo Nordisk A/S Stable non-aqueous liquid pharmaceutical compositions comprising an insulin

Also Published As

Publication number Publication date
CA2786953A1 (en) 2011-07-21
BR112012016853A2 (pt) 2017-10-17
JP2013517245A (ja) 2013-05-16
WO2011086093A2 (en) 2011-07-21
EP2523655A2 (en) 2012-11-21
JP5908847B2 (ja) 2016-04-26
KR20120117013A (ko) 2012-10-23
CN102753150A (zh) 2012-10-24
US20130058999A1 (en) 2013-03-07
RU2012133075A (ru) 2014-02-20
AU2011206629A1 (en) 2012-07-12
WO2011086093A3 (en) 2012-05-24
AU2011206629B2 (en) 2014-07-17
US20140255481A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX341324B (es) Polipeptidos.
IN2012DN06720A (es)
GB201118656D0 (en) New compounds
MX2013001677A (es) Formulaciones estables de linaclotida.
EP4414376A3 (en) Novel depsipeptide and uses thereof
MY188139A (en) Sodium channel modulators for the treatment of pain
MY172292A (en) Vectors and sequences for the treatment of diseases
TN2012000414A1 (en) Forms of rifaximin and uses thereof
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
MX349004B (es) Nuevos compuestos.
GB201209609D0 (en) New compounds
MX2013004061A (es) Analogos de ciclosporina.
WO2012174158A3 (en) Administration of benzodiazepine
MX339533B (es) Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PH12014501991B1 (en) Phenicol antibacterials
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
MX2015011109A (es) Composiciones estables de activador de glucoquinasa.
GEP201606514B (en) Apoptosis inhibitors and usage thereof
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies

Legal Events

Date Code Title Description
FA Abandonment or withdrawal